MINI FUTURE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 09:23:09 01/07/2024 pm IST | ||
| 4.455 EUR | +1.60% |
|
| 1 month | +32.88% | ||
| 3 months | +53.59% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 4.455 | +1.60% |
| 28/24/28 | 4.385 | +1.86% |
| 27/24/27 | 4.305 | -2.27% |
| 26/24/26 | 4.405 | -5.17% |
| 25/24/25 | 4.645 | +11.79% |
Real-time Euronext Paris
Last update July 01, 2024 at 09:23 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| NI4NB | |
| ISIN | NLBNPNL2NS68 |
| Date issued | 19/02/2024 |
| Strike | 680.3 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.735 € |
|---|---|
| Lowest since issue | 1.94 € |
| Spread | 0.01 € |
| Spread % | 0.23% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- NI4NB Certificat
